Coherus Oncology, Inc. (CHRS)
1.07
0.00 (0.00%)
USD |
NASDAQ |
Oct 09, 16:00
1.075
0.00 (0.00%)
Pre-Market: 20:00
Coherus Oncology Profit Margin (Quarterly) : -233.1% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -233.1% |
| March 31, 2026 | -300.0% |
| December 31, 2025 | -363.6% |
| September 30, 2025 | -384.7% |
| June 30, 2025 | -437.5% |
| March 31, 2025 | -623.7% |
| December 31, 2024 | -596.1% |
| September 30, 2024 | -786.5% |
| June 30, 2024 | -532.7% |
| March 31, 2024 | -2.95K% |
| December 31, 2023 | -87.03% |
| September 30, 2023 | -53.16% |
| June 30, 2023 | -73.01% |
| March 31, 2023 | -233.5% |
| December 31, 2022 | -129.8% |
| September 30, 2022 | -190.8% |
| June 30, 2022 | -83.37% |
| March 31, 2022 | -159.8% |
| December 31, 2021 | -62.32% |
| September 30, 2021 | -46.70% |
| June 30, 2021 | -34.12% |
| March 31, 2021 | -208.3% |
| December 31, 2020 | 8.79% |
| September 30, 2020 | 24.60% |
| June 30, 2020 | 43.51% |
| Date | Value |
|---|---|
| March 31, 2020 | 30.62% |
| December 31, 2019 | 31.67% |
| September 30, 2019 | 42.12% |
| June 30, 2019 | 28.25% |
| March 31, 2019 | -53.92% |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | -3.97K% |
| March 31, 2017 | -46.47K% |
| December 31, 2016 | -9.00K% |
| September 30, 2016 | 51.49% |
| June 30, 2016 | -498.6% |
| March 31, 2016 | -530.3% |
| December 31, 2015 | -515.6% |
| September 30, 2015 | -997.4% |
| June 30, 2015 | -859.8% |
| March 31, 2015 | -702.9% |
| December 31, 2014 | -447.0% |
| September 30, 2014 | -49.30% |
| June 30, 2014 | -504.9% |
| March 31, 2014 | -699.9% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Enanta Pharmaceuticals, Inc. | -135.8% |
| ACADIA Pharmaceuticals, Inc. | 10.23% |
| Alnylam Pharmaceuticals, Inc. | 12.74% |
| Anika Therapeutics, Inc. | 10.15% |
| Savara, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -197.4% |
| Return on Assets | -47.99% |
| Return on Invested Capital | -118.6% |
| Gross Profit Margin (Quarterly) | 64.33% |
| Operating Margin (Quarterly) | -226.0% |
| Return on Net Operating Assets | -221.5% |